Our Pipeline: Solid, And Set For Further Growth
Identifying and developing products that will improve the health and quality of life of patients remains a
primary focus of Forest Laboratories. Our current product pipeline includes therapies in all stages of
development and across a wide range of therapeutic areas, including cardiovascular disease, chronic obstructive
pulmonary disease (COPD), major depressive disorder (MDD), diabetes, infectious disease, and pain management.
The following is a partial listing of our pipeline products:
| Cariprazine |
Schizophrenia/Bipolar Mania |
NDA filed |
| Levomilnacipran (F2695) |
MDD |
NDA filed |
| Azimilide |
Arrhythmia |
Phase III |
|
| BYSTOLIC + Valsartan |
Hypertension |
Phase III |
|
| Ceftazidime + Avibactam |
Infectious Disease |
Phase III |
|
| TUDORZA + Formoterol |
COPD |
Phase III |
|
|
Proof of Concept
|
| BC-3781 |
Infectious Disease |
Phase II |
|
| Cariprazine |
MDD Adjunctive/Bipolar Depression |
Phase II |
|
| GK1-399 |
Diabetes |
Phase II |
|
| GRT6005 |
Pain Management |
Phase II |
|
| TEFLARO + Avibactam |
Infectious Disease |
Phase II |
|
Except for the historical information contained herein, this site contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of
risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for
new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch
of new products, and the risk factors listed from time to time in Forest Laboratories' Annual Report on
Form 10-K, Quarterly Reports on Form 10-Q, and any subsequent SEC filings. Forest assumes no obligation to
update forward-looking statements contained here to reflect new information or future events or developments.
